Tillman Gerngross, Adagio Therapeutics CEO

An­ti­body leg­end Till­man Gern­gross is el­bow­ing his way in­to the Covid-19 R&D cru­sade: 'I don’t see this end­ing any­time soon'

One of the most in­flu­en­tial — and out­spo­ken — sci­en­tists at work in the field of an­ti­body dis­cov­ery is jump­ing in­to the fren­zied race to cre­ate new …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.